In this interview, Chiara Nozzoli, speaks on her career journey and her work in haematopoietic stem cell transplantation, ...

When Dr. Filippo Milano left his home in Italy to study medicine in Seattle in 2008, it was supposed to be for six months, just long enough to learn how to do bone marrow transplant. Instead, he ...

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The approval of the Columvi combo, the first bispecific antibody regimen for DLBCL in Europe, follows a conditional marketing ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

This partnership spans allogeneic cell therapies currently in preclinical development for cancer. AstraZeneca also has the opportunity to improve on the manufacturability of autologous cell therapy.

Our research has shown that our allogeneic T-cell progenitors ... It has huge potential for applications in hematology post-transplant, as we are doing now in high-risk acute leukemia, but ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

BASEL, Switzerland I April 14, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Columvi® (glofitamab) in ...